in 1796 to protect against smallf documented use of a live attenua and the beginning of modern Since then there have been milestones in immunization, su vaccine (1925), yellow fever measles vaccine (1960) , rubella va mumps vaccine (1967) (for reN 1978) . One of the goals of im provide effective vaccines ag agents, whether they be vira parasitic. Up until now, effective many infectious agents, partici have proven to be elusive. I experiments indicate that new va be available.
Developments in moleculai immunochemistry and recombin nology have laid the found production of a new breed of va the antigens associated with ir and invasive agents are attribu molecules. Clearly then, kno molecular features responsible fo of protein molecules lies at understanding, in molecular ter events of the immune response. synthesis of antigenic sites on should afford valuable synthetic will, in principle, be expected to side effects.
Progress in defining prc structures has been very slow, ar the entire antigenic structure o proved to be extremely diffic studies from the laboratory of have resulted in the completi4 protein antigenic structures to b their entirety. These were the ant of sperm-whale myoglobin (Mb) 1975) and of hen egg-white ly. (Atassi 1978) . Because myoglob protein for which the entire an was determined, it has served system for investigating para mechanism and regulation o 0141-0768/84/040261-03/$01 .00/0 Journal of the Royal Society of Medicine Volume 77 April 1984-,26J response to protein antigens.he *ve prgem has five antigenic sites exposed 1 ation-6tious diseases in ally sensitive continuous portions of the polyrecognized for peptide chain. These antigenic sites are surpris-) recover from ingly small, and are only 5-7 amino acids in rom recurrences. length. ion with cowpox Following the determination of the entire pox was the first antigenic structure of Mb, detailed studies were
Lted viral vaccine carried out to investigate the antigenicity of the immunization. chemically synthesized antigenic sites and selected many historical putative non-antigenic surface regions of ich as pertussis myoglobin. Very interestingly, immunization of vaccine (1937), experimental animals with these synthetic antiiccine (1966) and genic sites demonstrated that they are effective in view see Cohen producing antibodies that bind to native Lmunology is to myoglobin (Young & Atassi 1982) . Of intriguing ainst infectious interest was the finding that immunization with Ll, bacterial or other synthetic peptides, representing surface vaccines against regions of the Mb molecule that are not antigenic ularly parasites, when intact Mb is the antigen, will also elicit -Iowever, recent antibodies that bind to native Mb (Young et al. ccines may soon 1983) . Thus it appears that synthetic peptides, or at least peptides of Mb, representing surface r immunology, locations of the molecule, are effective in ant DNA techproducing antibodies that will bind the native ations for the protein. Similar results have been obtained with ccines. Many of synthetic peptides of influenza virus haemagnmune disorders glutinin (Atassi & Webster 1983) . The ability to table to protein induce these antibodies can readily be exploited wledge of the to prepare monoclonal antibodies of preselected r the antigenicity specificities to desired protein antigens.
the basis of The finding that antibodies to native protein ins, the cellular can be elicitedby immunization with synthetic Localization and antigenic sites or other synthetic peptides, invasive agents representing surface locations of the molecule, vaccines, which has many implications. These immunogenic have little or no properties should afford simple tools for probing the mechanism of the immune response and for )tein antigenic therapeutic and diagnostic purposes in diseaseid elucidation of related antigens and invasive agents. It should tf a protein has thus be possible to produce a whole battery of cult. Pioneering new vaccines to antigens involved in infectious Professor Atassi diseases, once the surface peptides of the proteins on of the first involved have been identified. Herein lies the )e determined in problem, because until now it has been very tigenic structures difficult to identify these peptides; for example, it in 1975 (Atassi took over ten years of exhaustive research to sozyme in 1978 identify the antigenic sites of myoglobin¾ One can sin was the first pose the question that if it took over ten years for tigenic structure myoglobin, how long will it take to determine the as a valuable antigenic profile of agents of infectious diseases Lmeters of the which are considerably more complex? If the immune Recent experiments in nucleotide sequencing, however, have shed light on additional ways by which these important peptides (not necessarily antigenic sites) can be identified. For example, during the sequencing of Moloney leukaemia virus genome, an open reading frame was found whose coding capacity did not fit with the known biochemistry of the viral proteins. A peptide was then chemically synthesized from within the protein predicted by the nucleotide sequence and immunized into experimental animals. The resultant anti-peptide antibody precipitated a protein from the infected cells but not from normal cells (Sutcliffe et al. 1980 ). More recently, peptides corresponding to influenza HAl and rabies virus glycoprotein have been synthesized (Lerner 1982) . Thus, by this technique it is possible to identify peptides that can be used in synthetic vaccine production. Two particularly good examples of synthetic vaccines are those to foot and mouth disease virus (FMDV) and the hepatitis B virus. A third example could be added here, namely the possibility of a synthetic vaccine to the sporozoite stage of Plasmodium knowlesi. The foot and mouth disease virus contains one molecule of infectious single-stranded RNA and 60 copies of each of four polypeptides VPI-VP4 (Cooper et al. 1978) . The VP1 polypeptide isolated from virus particles has some immunogenic activity, whereas the other three viral polypeptides have no such activity (Meloen et al. 1979) . Application of recombinant DNA technology has allowed determination of the nucleotide sequence of the FMDV genome, from which the primary amino acid sequence of the VPI polypeptide was deduced. Peptides corresponding to several regions of VP1 polypeptide were chemically synthesized and then immunized into guinea' pigs. One of the synthetic peptides, -peptide 141-160, was capable of eliciting a protective antibody response after a single immunization (Bittle et al. 1982) . Preliminary data in cattle indicate that peptide 141-160 can elicit an antibody response sufficient to protect them against the disease. Thus the prospects for a totally synthetic vaccine against foot and mouth disease are very encouraging. Discovery of hepatitis virus-specific antigens and their association with the outer membrane of hepatitis B virus (HBV) has led to rapid advances in the prevention of HBV infection. For example, it has been shown that protective immunity can be induced by HBV surface antigen (HB.Ag) polypeptide-associated subviral particles (Hollinger et al. 1978) . Application of recombinant DNA methods has allowed determination of the nucleotide sequence of HBV DNA. From this nucleotide sequence was predicted the amino acid sequence of the product of the HB.Ag gene.
A peptide, termed the H peptide, corresponding to a region of the HB8Ag, was chemically, synthesized and immunized into mice. This peptide was effective in inducing the formation of antibodies to HBSAg (Prince et al. 1982 ). If anti-HBSAg confers immunity to infection with hepatitis B virus, as is generally thought, these findings may permit a practical solution to the problem of world-wide mass immunization against EBV. The sporozoite stage of Plasmodium protozoan parasites that cause malaria are covered with a highly immunogenic surface protein, the circumsporozoite protein . The structure of this protein could be important in understanding the sporozoite cell surface and the nature of its antigenic determinants (epitopes). Also, knowledge of its protein structure could lead to chemical synthesis of peptides that may be used as a malaria vaccine. Recently, the cloning of complementary DNA fragments of Plasmodium knowlesi surface antigen gene that contain the epitopes of the circumsporozoite protein has been reported. Complementary DNA clones that code for the immunogenic region of the Plasmodium knowlesi circumsporozoite protein contain a tandemly-repeating 36-base pair unit (Godson et al. 1983) . A dodecapeptide corresponding to this unit has been synthesized and shown to have the properties of the P. knowlesi surface antigen epitope, as judged by immunological criteria (Godson et al. 1983 ). The circumsporozoite proteins of the malaria parasite P. berghei and of the human malaria parasites, P. falciparum and P. vivax, have the same immunoreactive properties, suggesting that they also contain repeated epitopes and that such an unusual structural feature is common to sporozoite surface antigens of all species of Plasmodium (Zavala et al. 1983 ). Thus if equivalent peptides from the human malarias are immunogenic in vivo, they may be the basis of synthetic vaccines to the sporozoite stage.
It seems probable now that in the very near future many peptides of infectious organisms will be identified and used as synthetic peptide vaccines. However, there will still be one major problem to overcome before these synthetic peptide vaccines can be used in large-scale human immunization programmes, namely, the use of carriers or adjuvants in immunization. Since carriers, such' as bovine serum albumin or erythrocytes, and adjuvants such as complete Freund's adjuvant, cannot be used in human immunization, the question arises as to how humans might be immunized effectively with these peptides. One possible way of overcoming these problems is to construct live vaccines by using genetically-engineered viruses. Indeed, recently this has been reported for recombinant Journal of the Royal Society of Medicine Volume 77 April 1984 263 vaccinia virus expressing virus haemagglutinin (Panicali et al. 1983) . Here recombinant vaccinia viruses containing the cloned haemagglutinin (HA) gene from influenza virus were constructed. Intravenous immunization of rabbits with these recombinant poxviruses resulted in the production of antibodies reactive with influenza HA. Heterologous live vaccines using appropriately engineered vaccinia, which is itself a vaccine, seem almost an ideal generic immunogen. Vaccine strains currently available are generally safe, and it is reasonable to expect that additional modification of the virus by genetic engineering will result in an even safer virus. The efficacy of the virus, as a vaccine, is attested to by the successful world-wide eradication of smallpox. Furthermore, the vaccinia genome is sufficiently large to allow the construction of polyvalent vaccines.
Thus it seems likely that progress towards new human vaccines will be by a combination of synthetic peptide immunotechnology and recombinant DNA studies. Appropriately engineered recombinant viruses, such as vaccinia viruses, could be used for the production of live vaccines against human diseases. Viral, bacterial and parasitic infectious agents may well be amenable to control through such approaches.
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